
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Panel members discuss the standards and regulations set for facilities to be considered a PCMH. Dr. Pawlson talks about the standards developed by the NCQA and what they mean.






